CEL-SCI (CVM) said Wednesday that it has completed its Breakthrough Medicine Designation application to the Saudi Food and Drug Authority for its Multikine investigational cancer medicine.
The company said it expects its prospective Saudi partner to formally submit the application to the Saudi regulator on its behalf in the coming weeks.
The company said Multikine would immediately become available for patient access and reimbursement under the regulator's Breakthrough Medicine Designation program, which typically takes 60 days for an application response.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。